CCM Duopharma partners India’s Natco and Biocon to offer affordable cancer and insulin therapies

CCM Duopharma Biotech Bhd (CCMD) has partnered with India’s Natco Pharma Limited (Natco) and Biocon Limited (Biocon) to offer affordable cancer and insulin therapies in Malaysia.
CCMD, a subsidiary of Chemical Company of Malaysia Bhd (CCM), signed a 15-year partnership with Natco to build Malaysia’s first High Active Potent Ingredient Drug (HAPI) manufacturing facility to produce generic oncology medicines.
The signing ceremonies, held earlier today, were witnessed by Prime Minister Datuk Seri Najib Tun Razak who was in India for a five-day official visit.
In a statement, CCMD said Natco will provide facility design, manufacturing technology transfer as well as active pharmaceutical ingredients (API) to localize the manufacturing of eight cancer products in Malaysia over the next seven years.
It said the project has been proposed for the Entry Point Project under the National Key Economic Areas by government delivery unit, PEMANDU and will see CCMD allocate a total investment of RM34 million.
Separately, CCMD has also been authorized by Biocon to be the reseller of human insulin in Malaysia following the award of a RM300 million contract under the Ministry of Health’s Off Take programme.
The programme will supply human insulin to all government hospitals and clinics for a period of three years until Dec 1, 2019.
Chairman of CCM, Datuk Normala Abdul Samad, said the strategic alliances with global leaders such as Biocon and Natco solidifies their position as a key player in the Malaysian pharmaceutical industry.
“It is also a stepping stone to help us move up the pharma industry value chain in Asia, and strengthen our capabilities from developing generic pharmaceuticals, leveraging on the expiry of innovator patents to marketing and distribution.
“Through the partnerships, we also hope to offer Malaysians and those in neighbouring countries affordable and high quality treatment options in line with our philosophy ‘Enhancing Quality of Life’,” she added.

Source: http://www.malaysiastock.biz/Blog/BlogArticle.aspx?tid=5511

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more